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Abstract
A liver, heart, iliac vessel, and two kidneys were recovered from a 39-year-old man who died of 
traumatic head injury and were transplanted into five recipients. The liver recipient eighteen days 
post-transplantation presented with headache, ataxia and fever, followed by rapid neurologic 
decline and death. Diagnosis of granulomatous amebic encephalitis (GAE) was made on autopsy. 
Balamuthia mandrillaris infection was confirmed with immunohistochemical and PCR assays. 
Donor and recipients' sera were tested for B. mandrillaris antibodies. Donor brain was negative for 
Balamuthia by immunohistochemistry and PCR; donor serum Balamuthia antibody titer was 
positive (1:64). Antibody titers in all recipients were positive (range, 1:64 to 1:512). Recipients 
received a 4- to 5-drug combination of miltefosine or pentamidine, azithromycin, albendazole, 
sulfadiazine, and fluconazole. Nausea, vomiting, elevated liver transaminases and renal 
insufficiency was common. All other recipients survived and have remained asymptomatic 24-
months post-transplant. This is the third donor-derived Balamuthia infection cluster described in 
solid organ transplant recipients in the U.S. As Balamuthia serologic testing is only available 
through a national reference laboratory, it is not feasible for donor screening, but may be useful to 
determine exposure status in recipients and to help guide chemotherapy.
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In February 2012, the U.S. Centers for Disease Control and Prevention (CDC) was asked to 
evaluate brain sections from a liver transplant recipient who, eighteen days post-
transplantation in November 2011, presented with headache, ataxia, fever, rapid neurologic 
decline and progressed to death. Diagnosis of granulomatous amebic encephalitis (GAE) 
was made on autopsy and Balamuthia mandrillaris infection was confirmed with 
immunohistochemical and PCR assays at CDC. Organs procured from the same donor 
included (in addition to the liver): heart, iliac vessel, and two kidneys transplanted into four 
recipients.
When the liver recipient became ill the host organ procurement organization (OPO) and 
transplant centers were contacted about a potential donor derived infection. All recipients 
were well and without evidence of disease. The CDC confirmed the diagnosis of Balamuthia 
in the liver recipient and notified the transplant center of the findings. The liver recipient's 
transplant center rapidly notified the organ procurement organization, who, in turn, notified 
the Organ Procurement and Transplantation Network (OPTN). A public health investigation 
was undertaken directed by the CDC to evaluate the other recipients for exposure to B. 
mandrillaris and to provide serologic testing to monitor response to anti-Balamuthia 
medications.
Balamuthia mandrillaris is a free-living ameba that is distributed in the natural environment. 
Infection is rare with fewer than 200 cases reported worldwide; however, it is likely that this 
entity is misdiagnosed as other types of encephalitis or neurologic disease (1-3). The exact 
ecological niche is unknown, but the organism has been isolated on several occasions from 
soil, dust and water (1, 4-6,7). Disease caused by Balamuthia appears to be associated with 
contact with soil or stagnant water. Balamuthia disease affects both immunocompetent and 
immunocompromised patients with underlying co-morbidities such as HIV infection, 
diabetes and drug abuse; it appears to occur more frequently in persons of Hispanic ethnicity 
(1-3, 8-11).
Balamuthia cysts and trophozoites can be introduced into the body through inhalation into 
the lower respiratory tract and through ulcerated or broken skin. Disease can occur weeks to 
months after exposure, and manifests typically as encephalitis, known as granulomatous 
amebic encephalitis (GAE). Symptoms of central nervous system (CNS) infection include 
headache, stiff neck, nausea, fever and changes in mental status. Skin involvement, if 
present, appears as papular, erythematous lesions which evolve to violaceous plaques. 
Optimal treatment is undefined but consists typically of three or more of the following 
agents administered for a prolonged period: macrolides, pentamidine, antifungal agents 
(amphotericin B, azoles, flucytosine), albendazole, sulfadiazine and miltefosine (12-14). 
Despite aggressive combination antimicrobial therapy the disease is associated with high 
mortality.
Two clusters of donor-derived Balamuthia infection have been described previously in the 
United States (10, 15). Of eight organ recipients exposed in these two clusters, four 
developed GAE and three of the four died. Four patients without proven infection were 
Gupte et al. Page 2













administered preemptive therapy of variable duration. Herein, we describe a third 
transmission of Balamuthia through organ transplantation among five solid organ transplant 
(SOT) recipients and use of serologic testing to monitor response to therapy in four patients.
Methods
Epidemiologic Investigation
We reviewed donor and recipient medical records and conducted patient interviews to 
characterize clinical history, potential risk factors for infection, diagnostic studies and 
outcomes.
Laboratory Investigation
Recipient cerebrospinal fluid (CSF) and heart-recipient lung biopsy samples were processed 
for culture as follows. The CSF was divided into two aliquots; one aliquot was inoculated 
into human lung fibroblast (HLF) cell monolayer and the other aliquot was used to extract 
DNA for PCR analysis. Lung biopsy tissue was minced and inoculated into a different HLF 
monolayer. The HLF flasks inoculated with the CSF and lung samples were incubated at 
37°C and examined daily under an inverted microscope equipped with phase contrast optics 
(16).
Donor and recipient serum samples were tested by an immunofluorescence assay (IFA as 
described previously) (17). Serum samples were considered to be positive for exposure in 
transplant patients if ≥1:64. Additionally, IFA was performed on tissue sections using anti-
Acanthamoeba castellanii and anti-Balamuthia mandrillaris sera as described previously 
(16).
Immunohistochemical assays (IHC) were performed on tissue samples using a polymer-
based indirect immunoalkaline phosphatase detection system with colorimetric detection of 
antibody/polymer complex with Fast Red Chromogen (Thermo Fisher Scientific or Biocare 
Medical). Tissues were evaluated with a pool of anti-amoebic antibodies which include a 
rabbit polyclonal against Naegleria fowleri, rabbit polyclonal against Acanthamoeba 
culbertsoni, and a rabbit polyclonal against Balamuthia mandrillaris.
DNA was extracted directly from formalin fixed clinical samples using the DNeasy blood 
and tissue DNA extraction kit (QIAGEN, Valencia, CA). Samples were tested by PCR using 
a TaqMan assay that detects Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria 
fowleri as described elsewhere (18).
Results
An autopsy of the liver transplant recipient was performed. Results were suggestive of GAE 
and the specimens were sent to the CDC for evaluation. Laboratory testing confirmed the 
diagnosis as GAE caused by Balamuthia mandrillaris. The donor's organ procurement 
agency was notified as described above, and an investigation was initiated.
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The donor was a 39-year-old white man who presented to an emergency room with head 
trauma secondary to an assault in October, 2011. He was lethargic, confused and potentially 
had an unwitnessed seizure per his mother's report. He had been involved in an altercation 
and sustained a contusion on his posterior scalp. Past medical history included seizure 
disorder, for which he received carbamazapine, substance abuse and previous homelessness. 
He was incarcerated briefly in 1997 and 2011. On presentation he was afebrile. His white 
blood cell count was elevated (18,600 cells/μL). A toxicological screen was positive for 
cocaine. Head CT imaging showed bilateral frontal and temporal contusions and a left 
parietal contusion. Two days post-admission cerebral perfusion studies showed no blood 
flow. He died the next day with cause of death documented as blunt head trauma/homicide. 
Permission from the family was granted for organ donation. The heart, liver, iliac vessel, 
and kidneys were recovered; no other tissues were procured.
After the liver recipient was diagnosed with GAE post-mortem, immunohistochemical 
(IHC) testing was performed by the CDC on donor brain, lung, and kidney tissue which was 
negative for Balamuthia and other free-living amebae. Formalin-fixed brain and lung tissue 
were also PCR-negative for Balamuthia and other free-living amebae. Archived serum and 
plasma from the donor, drawn at time of organ procurement, were positive for anti-
Balamuthia antibodies with titers of 1:64 obtained on both samples when tested with IFA.
Liver Recipient
The liver recipient was a 58-year-old white male with a history of cirrhosis and end-stage 
liver disease secondary to hepatitis C virus infection (Table 1). His immediate post-operative 
course was uneventful and he was discharged 10-days post-transplant. He presented eight 
days after discharge complaining of headaches for one week, neck stiffness, ataxia and 
fever. Shortly thereafter, he developed altered mental status and neuroimaging revealed 
multiple brain infarcts and moderate edema. CSF studies showed neutrophilic pleocytosis 
(975cells/μL; 63% polymorphs, 20% macrophages, 16% lymphocytes and 1% eosinophils). 
CSF protein was elevated (221mg/dL) and CSF glucose was normal. Blood, CSF, and urine 
cultures were negative. CSF was negative for cryptococcal antigen, but positive for 
Toxoplasma IgG. He had a rapid neurologic decline and care was withdrawn by the family 
12 days after admission. Samples of brain tissue from autopsy were consistent with ameba 
on histopathologic examination (Figure 1) and were positive for Balamuthia by IHC and 
PCR.
Heart Recipient
The heart recipient was a 62-year-old white male with a history of ischemic 
cardiomyopathy. Approximately four months after transplantation he underwent evaluation 
for Balamuthia exposure with serologic testing, brain imaging and lumbar puncture (Table 
1). Microscopic examination of the Human Lung Fibroblast culture of one CSF sample 
revealed a few unusual cells approximately 30 μm in size, with pseudopodial movement and 
nuclear morphology similar to that of Balamuthia and other free-living amebas (Figure 2). 
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These cells failed to grow in culture and decayed. Initial serology for Balamuthia antibodies 
was positive at 1:512 (Figure 3).
He was administered initial Balamuthia treatment using the following medications: 
azithromycin 20 mg/kg daily; albendazole 400 mg bid; fluconazole 400 mg daily; 
sulfadiazine 1.5grams every 6 hrs; pentamidine 4mg/kg IV daily (replaced with miltefosine 
50 mg tid two days later). During his course of therapy her developed weight loss, anorexia 
and nausea and was admitted on several occasions for acute kidney injury and elevated liver 
function tests (Table 1). Several medications (miltefosine, albendazole) were discontinued 
and then restarted when he improved. Balamuthia titers decreased to negative (1:16) over a 
110-day period (Figure 3).
Iliac Vessel Recipient
The vessel recipient was a 61-year-old white male with a history of cirrhosis secondary to 
alcohol use, complicated by hepatocellular carcinoma (Table 1). In October 2012 he 
received an iliac vessel graft from the donor for use as a vascular conduit. He received a 
liver transplant from a different donor. Four months after transplantation he underwent 
evaluation for Balamuthia exposure with serologic testing, brain imaging and lumbar 
puncture. CSF samples were PCR-negative for Balamuthia and other free-living ameba. 
Initial serology for Balamuthia antibodies was positive (1:128; Figure 3).
Balamuthia treatment was begun with the following: azithromycin 20 mg/kg daily; 
albendazole 400mg bid; fluconazole 400mg daily; pentamidine 4mg/kg IV daily (replaced 
with miltefosine 50 mg tid five days later). During his treatment course he developed 
intermittent nausea, anorexia, malaise and elevated liver function tests that necessitated 
discontinuing of some medications and re-starting medications when laboratory 
abnormalities improved. Balamuthia titers decreased to negative (1:8) over a 160-day period 
(Figure 3)
Left Kidney Recipient
The left kidney recipient was a 69-year-old black male with a history of hypertension and 
diabetes (Table 1). Approximately four months after transplantation he underwent serologic 
testing, brain imaging and lumbar puncture. Initial serology for Balamuthia antibodies was 
positive at 1:256 (Figure 3). CSF PCR was negative for Balamuthia and other free-living 
amebae.
Balamuthia treatment was initiated with the following: azithromycin 20 mg/kg daily (1,000 
mg PO daily); albendazole 400 mg PO bid; fluconazole 400 mg PO daily; pentamidine 
4mg/kg IV daily (300 mg IV daily replaced with miltefosine 50 mg tid 7 days later); 
sulfadizine 1.5 grams PO Q6 hours. The patient remained this regimen throughout the 
duration of treatment (162 days). Adverse drug effects included diarrhea and mild AST and 
ALT elevation. Balamuthia antibody titers decreased to negative (1:16) by approximately 
100 days after initiation of treatment (Figure 3).
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The right kidney recipient was a 60-year-old female with a history of diabetes and 
hypertension (Table 1). As part of her evaluation she had serum testing which revealed an 
initial antibody titer for Balamuthia of 1:128. Her initial regimen included clarithromycin 
1000 mg daily and fluconazole 400mg daily, drugs she could obtain while she was 
travelling. Several days later miltefosine was added and azithromycin was substituted for 
clarithromycin Adverse effects included unsteadiness, inability to walk, nausea, postprandial 
vomiting and intermittent hallucinations. She developed dehydration, acute kidney injury 
(Cr 9.7 mg/dL), and tacrolimus toxicity (level> than 60 ng/ml), requiring hospitalization and 
temporary discontinuations of several medications. The Balamuthia serology was negative 
(1:16) approximately 90 days after initiation of medications.
Discussion
We describe donor-derived Balamuthia exposure among four SOT recipients and one 
recipient of an iliac vessel, one of whom developed GAE and died. B. mandrillaris is an 
uncommon pathogen but is emerging as a cause of donor-derived infection (2, 11, 19). 
Transplant professionals should consider Balamuthia as a potential cause of unexplained 
encephalitis in organ donors and recipients; however, it important to note that our donor did 
not have any signs of encephalitis or skin lesions consistent with Balamuthia disease.
There have been two previous recent reports of donor-derived Balamuthia infection in the 
US (10, 15). In the first, the donor was a four-year-old boy who developed a febrile illness, 
seizures and headache (10). Donor brain tissue from autopsy showed amebae 
histopathologically consistent with Balamuthia and PCR was positive for Balamuthia. Two 
of the four organ recipients (right and left kidney) developed Balamuthia encephalitis and 
were treated with a combination of pentamidine, sulfadiazine, flucytosine, fluconazole, 
azithromycin, and later miltefosine; one progressed to death three months post-transplant. 
The heart recipient did not develop Balamuthia antibodies but was nonetheless treated 
empirically (pentamidine, azithromycin and fluconazole) and remained asymptomatic. The 
seropositive liver recipient was treated with pentamidine, azithromycin, fluconazole and 
sulfadiazine.
The second cluster occurred in 2010 (15). The organ donor was a Hispanic male with a 
chronic skin lesion who died of presumed stroke. The liver and kidney-pancreas recipients 
developed fatal encephalitis 18 days and 24 days post-transplant. Two other recipients 
(heart, second kidney) remained asymptomatic and were given prophylactic therapy with 
multi-drug combinations.
The donor associated with this third cluster had no skin lesions, no fever at time of death, 
and a negative brain biopsy for Balamuthia; nevertheless, transplant-associated transmission 
of Balamuthia from his donor due to amebae in his blood and/or organ tissues likely 
occurred. The donor was seropositive (1:64) and all of the recipients of his tissues were 
seropositive (>1:64), suggesting potentially efficient (100%) transmission. Further, GAE 
occurred in the liver recipient. The identification of an ameba-like organism in the CSF of 
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the asymptomatic heart recipient who had the highest serum antibody titer (1:512) among all 
the recipients is also suggestive, although the cells failed to grow in culture.
In this cluster described herein, a gradual reduction in titers to negative levels (1:16) was 
achieved in all asymptomatic recipients over a period of 306 days post transplantation; 
maximum duration of Balamuthia treatment was 175 days. Previously, in non-transplant 
clusters, serum samples were considered positive for titers ≥1:128 (17). Because of 
immunosuppression in transplant patients, lower titers to Balamuthia might be found with 
infection, so exposure in transplant patients is considered to be a titer of ≥1:64 and a two-
fold reduction in titers is considered to be seronegative under these circumstances (17, 24).
Organ donor screening has reduced the risk of transmission of many important pathogens 
such as HIV and hepatitis C virus. If a recipient is thought to potentially have a transplant-
transmitted illness, Organ Procurement and Transplantation Network (OPTN) policy 
requires reporting of potential donor-derived disease from both OPOs and transplant centers. 
The transplant center should notify the OPO and evaluation of other recipients should occur. 
OPTN should be notified by the OPO and transplant center. Any illness of uncertain cause 
found to be present in more than one recipient should be immediately reported to the OPO, 
OPTN, and public health authorities upon discovery by treating healthcare providers (25).
Because of the rarity of Balamuthia infection among SOT recipients and lack of an FDA 
approved screening test, laboratory donor screening is not feasible or justified, highlighting 
the importance of communication between the OPO and transplant centers. We used a 
serologic screening test developed at the CDC to identify infected but asymptomatic patients 
and to monitor patients monthly while receiving therapy. In all cases, negative titers (≤1:16) 
were achieved before medicines were discontinued. All patients at risk also received lumbar 
punctures with CSF studies sent for culture and PCR. Tissue biopsies for 
imunohistochemistry from brain or skin lesions may also be helpful to determine 
Balamuthia infection, if present.
Although combination Balamuthia therapy has led to successful in cases of GAE (12, 
20-23), effective treatment for B. mandrillaris disease has not been established. Mortality is 
high and optimal medications combinations are undefined; GAE has been treated in the past 
with various combinations of macrolides, pentamidine, antifungal agents (amphotericin B, 
azoles, flucytosine), sulfadiazine, albendazole, miltefosine, and additional drugs. The 
advantages of medications for patients exposed to Balamuthia are unclear. In the three 
transplant-associated clusters to date, none of the asymptomatic patients exposed to 
Balamuthia through solid-organ transplantation who received empiric therapy developed 
GAE; however, side effects were problematic. In our cluster, prolonged (range, 68-175 
days) empiric therapy was given to our asymptomatic recipients, which proved challenging. 
We added miltefosine to the regimen, as it has been used with some success with other 
therapies for Balamuthia GAE and was used similarly in a previous cluster (10, 12). Most 
patients in our 2012 cluster developed nausea, vomiting, malaise, dehydration, renal 
insufficiency, and abnormal liver studies. Three patients required admission because of 
adverse drug effects and only one patient tolerated a five-drug regimen without interruption 
for the treatment duration. Additionally, abnormal drug levels of immunosuppressive agents 
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caused by interactions with the anti-Balamuthia regimen were noted. Administrative issues 
also arose as emergency Food and Drug Administration (FDA) investigational new drug 
protocols and Institutional Review Board (IRB) approvals were required to obtain 
miltefosine.
This investigation was limited by the inability to identify Balamuthia in culture or by PCR 
in the organ donor and surviving organ recipients. Formalin fixed tissue available from the 
organ donor, is not the optimal specimen for PCR as formalin may interfere with test 
performance. The serologic assay is experimental and has not been validated in the post-
transplant population; however, given the specificity of the assay, it is unlikely that the 
positive serologic results in this cluster are secondary to cross-reactivity (16,17). This, 
coupled with positive serologic findings in all recipients and the donor, suggests donor-
derived exposure.
In summary, we describe a cluster of donor-derived Balamuthia transmission in solid organ 
transplant recipients. Only one of five exposed patients developed encephalitis. To date 
among three transplant clusters, symptomatic organ recipients have received chemotherapy 
for treatment of transplant-transmitted GAE and asymptomatic organ recipients have 
received prophylactic chemotherapy, guided by serology, for presumed B. mandrillaris 
exposure. Asymptomatic organ recipients in the 2012 cluster were considered exposed and 
received chemotherapy if serologies reached ≥1:64 and continued therapy, adjusted for side 
effects, until their serologies fell to 1:16 or lower. Although the serological treatment points 
were experimental and require further confirmation, and optimal preemptive therapy 
regimens are undefined, asymptomatic organ recipients in these three clusters who had 
initial titers ≥1:64 and who were managed in this way did not develop GAE.
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Figure 1. Liver recipient autopsy findings
CNS sections of the liver recipient stained with H&E (A & C) and reacted with the anti-
Balamuthia antibodies (B & D). A. Large numbers of Balamuthia amebae (at arrows) are 
seen around a blood vessel. H&E, ×200. B. A similar section reacted with the anti-
Balamuthia antibodies in the immunofluorescence test. Balamuthia amebae around the 
blood vessel are intensely fluorescing, staining bright apple green. ×200. C. Large numbers 
of Balamuthia (at arrows) around a blood vessel. Note the darkly staining nucleus. A CNS 
section stained with H&E. One ameba is seen with double nucleolus (big arrow), × 1,000. D. 
A section as in B with large numbers of intensely staining apple green amebae are seen 
around a blood vessel, × 1,000.
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Figure 2. Heart recipient CSF
A cell with the characteristic morphology of an ameba in the HLF CSF culture of the heart 
transplant recipient. Note the nucleus (N) and nucleolus (nu); phase contrast, ×600.
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Recipient Balamuthia serologies. Days on x-axis represent days from initial serologic 
testing. Initial serologic testing in all patients occurred approximately 4 months post-
transplant.
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